KIT and myocardial infarction: Recently, initial results of a randomized phase 1 trial [11] suggested intracoronary infusion of autologous c-kit+ CSCs was effective in improving LV systolic function and reducing infarcted size after myocardial infarction, thus, demonstrating that c-kit+ CSCs might be a perspective candidate for MI therapy.